AbbVie Inc (ABBV) : Baldwin Investment Management reduced its stake in AbbVie Inc by 2.22% during the most recent quarter end. The investment management company now holds a total of 19,492 shares of AbbVie Inc which is valued at $1,297,582 after selling 443 shares in AbbVie Inc , the firm said in a disclosure report filed with the SEC on Aug 2, 2016.AbbVie Inc makes up approximately 0.55% of Baldwin Investment Management’s portfolio.
Other Hedge Funds, Including , Royal London Asset Management Ltd reduced its stake in ABBV by selling 70,641 shares or 11.41% in the most recent quarter. The Hedge Fund company now holds 548,532 shares of ABBV which is valued at $36,515,775. AbbVie Inc makes up approx 0.58% of Royal London Asset Management Ltd’s portfolio.Clarivest Asset Management reduced its stake in ABBV by selling 1,276 shares or 0.24% in the most recent quarter. The Hedge Fund company now holds 540,810 shares of ABBV which is valued at $35,817,846. AbbVie Inc makes up approx 1.02% of Clarivest Asset Management’s portfolio.North Star Asset Management Inc boosted its stake in ABBV in the latest quarter, The investment management firm added 175 additional shares and now holds a total of 17,986 shares of AbbVie Inc which is valued at $1,191,213. AbbVie Inc makes up approx 0.13% of North Star Asset Management Inc’s portfolio.Duncker Streett Co Inc boosted its stake in ABBV in the latest quarter, The investment management firm added 551 additional shares and now holds a total of 57,185 shares of AbbVie Inc which is valued at $3,648,975. AbbVie Inc makes up approx 1.26% of Duncker Streett Co Inc’s portfolio.Bnp Paribas Arbitrage Sa reduced its stake in ABBV by selling 411,443 shares or 33.52% in the most recent quarter. The Hedge Fund company now holds 815,847 shares of ABBV which is valued at $52,344,744. AbbVie Inc makes up approx 0.23% of Bnp Paribas Arbitrage Sa’s portfolio.
AbbVie Inc closed down -0.2 points or -0.30% at $66.34 with 53,09,293 shares getting traded on Monday. Post opening the session at $66.38, the shares hit an intraday low of $65.75 and an intraday high of $66.67 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, AbbVie Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $1.20. The company had revenue of $6452.00 million for the quarter, compared to analysts expectations of $6207.43 million. The company’s revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 EPS.
Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by Morgan Stanley to ” Equal-Weight” on Jun 8, 2016.
AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.